Literature DB >> 16140023

Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs.

Anna Ollerstam1, Sandra A G Visser, Anna H Persson, Göran Eklund, Lars B Nilsson, Tomas Forsberg, Stig Johan Wiklund, Johan Gabrielsson, Göran Duker, Ahmad Al-Saffar.   

Abstract

INTRODUCTION: To assure drug safety, the investigation of the relationship between plasma concentration and drug-induced prolongation of the QT interval of the ECG is a challenge in drug discovery. For this purpose, dofetilide was utilized to demonstrate the benefits of characterizing the complete time course of concentrations and effect in conscious beagle dogs in the assessment of drug safety.
METHOD: On two separate occasions, four male and two female beagle dogs were given vehicle or the test substance, dofetilide (0.25 mumol/kg), over a 3-h intravenous infusion. Cardiovascular parameters, including QT intervals, were recorded for 24-h using radiotelemetry. The QT interval was corrected individually for heart rate, vehicle treatment, and serial correlation (QT(c)). Exposure (plasma concentration) to dofetilide was measured and described by a two-compartment model. The individual concentration-time course of dofetilide was linked to the QT(c) interval via an effect compartment and a pharmacodynamic E(max) model, to account for the observed hysteresis.
RESULTS: Dofetilide induced a concentration-dependent increase in the QT(c) interval, with an EC(50) of 9 nM (3-30 nM, 95% C.I.) and an E(max) of 59+/-9 ms. A hysteresis loop was observed by plotting plasma concentrations vs. QT interval in time order, indicating a delay in onset of effect. It was found to have an equilibrium half-life of 11+/-8 min. Based on the parameters potency and E(max), a representation was made of the drug-induced changes to the QT interval. DISCUSSION: An effect compartment model was found to accurately mimic the QT interval prolongation following administration of the test substance, dofetilide. The assessment of the individual concentration-effect relationship and confounding factors such as hysteresis might provide a better prediction of the safety profiles of new drug candidates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140023     DOI: 10.1016/j.vascn.2005.07.002

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  8 in total

1.  Model-based evaluation of drug-induced QTc prolongation for compounds in early development.

Authors:  Vincent F S Dubois; Huixin Yu; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

Review 3.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 4.  Integrated risk assessment and predictive value to humans of non-clinical repolarization assays.

Authors:  Robert M Wallis
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

5.  Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.

Authors:  Anne S Y Chain; Vincent F S Dubois; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.

Authors:  V F S Dubois; E Casarotto; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2016-09-07       Impact factor: 8.739

7.  Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.

Authors:  V F S Dubois; W E A de Witte; S A G Visser; M Danhof; O Della Pasqua
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

Review 8.  Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.

Authors:  Hugo M Vargas; Michael G Rolf; Todd A Wisialowski; William Achanzar; Anthony Bahinski; Alan Bass; Charles T Benson; Khuram W Chaudhary; Nicolas Couvreur; Corina Dota; Michael J Engwall; C Michael Foley; David Gallacher; Andrea Greiter-Wilke; Jean-Michel Guillon; Brian Guth; Herbert M Himmel; Christa Hegele-Hartung; Maki Ito; Stephen Jenkinson; Katsuyoshi Chiba; Armando Lagrutta; Paul Levesque; Eric Martel; Yoshiko Okai; Ravikumar Peri; Amy Pointon; Yusheng Qu; Ard Teisman; Martin Traebert; Takashi Yoshinaga; Gary A Gintant; Derek J Leishman; Jean-Pierre Valentin
Journal:  Clin Pharmacol Ther       Date:  2020-09-24       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.